GSK3A and neoplasm: SM0014 (AM), whose tumor demonstrated a BRAF fusion, harbored evidence of both MAPK and PI3K pathway activation based on multiple phosphorylation events (BRAF S445, MEK1/2 S217/221, ERK1/2 T202/Y204, GSK3a/b S21/9, p70S6 kinase S371, P70S6 kinase T389, Akt T308).